QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=A6B976409D9F41D60CDCCC916EFAD69C;jsessionid=0100CF5758C17AC1F8B5D889E1C5BA1C;jsessionid=6260465E51283220676A9BCAD17A3DA1;jsessionid=95B85CBA091C2FC849823B9B97DC92AA;jsessionid=5524BA63B93115283968CA5A9317AE3A;jsessionid=8F1C807114B0C81039BC2977FC2EF0A8 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=A6B976409D9F41D60CDCCC916EFAD69C;jsessionid=0100CF5758C17AC1F8B5D889E1C5BA1C;jsessionid=6260465E51283220676A9BCAD17A3DA1;jsessionid=95B85CBA091C2FC849823B9B97DC92AA;jsessionid=5524BA63B93115283968CA5A9317AE3A;jsessionid=8F1C807114B0C81039BC2977FC2EF0A8